Publications
Spotlight Publication
Balstilimab (PD-1 Antagonist), Botensilimab (Fc-Enhanced CTLA-4 Antagonist)
Botensilimab plus balstilimab in an expanded cohort of 123 patients with metastatic microsatellite stable colorectal cancer and no active liver metastases
Jul 4, 2025
Schlechter, et al.
Filter by
AGEN2373 (CD137 Agonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects.
Galand, et al.
AGEN2373 (CD137 Agonist)
American Society of Clinical Oncology (ASCO)
Jun 3
- Jun 7, 2021
Initial Findings of the First-in-human Phase I Study of AGEN2373, a Conditionally Active CD137 Agonist Antibody, in Patients (pts) With Advanced Solid Tumors.
Tolcher, et al.
AGEN1571 (ILT2 Antagonist)
American Association for Cancer Research (AACR)
Apr 8
- Apr 12, 2022
AGEN1571 is a novel high-affinity ILT2 antagonist antibody that promotes adaptive and innate immune responses.
Udartseva, et al.
AGEN1327 (TIGIT Antagonist)
Cancer Cell
Jun 11, 2018
Selective FcgR Co-Engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.
Waight, et al.
AGEN1327 (TIGIT Antagonist)
Society for Immunotherapy of Cancer (SITC)
Nov 9
- Nov 14, 2020
Anti-TIGIT antibodies require enhanced FcγR co-engagement for optimal T and NK cell-dependent anti-tumor immunity.
Ward, et al.
AGEN1327 (TIGIT Antagonist)
American Association for Cancer Research (AACR)
Mar 29
- Apr 3, 2019
FcgR Co-Engagement by Anti-TIGIT Monoclonal Antibodies Enhances T cell Functionality and Antitumor Immune Responses.
Chand, et al.